e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance
Law Stephanie, Benedetti Andrea, Oxlade Olivia, Schwartzman Kevin, Menzies Dick
Source:
Eur Respir J 2014; 43: 566-581
Journal Issue:
February
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Law Stephanie, Benedetti Andrea, Oxlade Olivia, Schwartzman Kevin, Menzies Dick. Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. Eur Respir J 2014; 43: 566-581
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis
Source: Eur Respir J 2010; 36: 870-877
Year: 2010
Predicting outcomes and drug resistance with new standardised treatment
Source: Eur Respir J 2011; 37: 974
Year: 2011
Appreciation efficiency of standard and alternative antituberculosis preventive therapy in children from different tuberculosis infection sources
Source: Eur Respir J 2006; 28: Suppl. 50, 28s
Year: 2006
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses
Source: Eur Respir J, 50 (1) 1700061; 10.1183/13993003.00061-2017
Year: 2017
Comparison of the efficacy of two methods of treatment, standard and modified, on patients with Isoniazid resistant tuberculosis
Source: Annual Congress 2007 - Difficult tuberculosis cases II
Year: 2007
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis
Source: Eur Respir J 2012; 39: 626-634
Year: 2012
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation
Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB)
Year: 2006
The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence
Source: Eur Respir J 2001; 18: Suppl. 33, 468s
Year: 2001
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection
Source: Eur Respir J 2015; 45: 569-571
Year: 2015
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection
Source: Eur Respir J 2015; 45: 571-574
Year: 2015
Is standardized treatment appropriate for non-XDR multiple drug resistant TB?
Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2008
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019
The main clinical problem of increasing resistance of
Mycobacterium tuberculosis
(MT) to first-line anti-TB drugs
Source: Eur Respir J 2005; 26: Suppl. 49, 654s
Year: 2005
The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Prevalence of inappropriate tuberculosis treatment regimens: a systematic review
Source: Eur Respir J 2012; 39: 1012-1020
Year: 2012
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004
Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
Year: 2006
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept